BioSeek, a Burlingame, Calif., developer of drug-screening technologies that use human cells, raised $10 million in a third funding round from San Diego-based Amylin Pharmaceuticals. The two companies also formed a partnership in which BioSeek will screen Amylin’s collection of protein fragments, or peptides, to identify possible drugs for treating inflammatory diseases.

As part of that collaboration, BioSeek can select two of Amylin’s peptides for development in diseases outside of Amylin’s own sphere of interest. The new partnership grew out of a previous collaboration (PDF) the two companies struck last August.

The BioSeek release is here.